Doxorubicin plus Interleukin-2 Chemoimmunotherapy against Breast Cancer in Mice

摘要: As recently characterized, following s.c. implantation into syngeneic C57BL/6 mice, E0771 tumor invades locally dermal layers and peritoneum, metastasizes to the lung, induces a nonspecific immunosuppression in host. Using this breast medullar adenocarcinoma model, therapy consisting of single moderate dose doxorubicin followed by twice daily doses interleukin-2 for 30 days was examined efficacy mechanism action when given animals with established disease. This combination treatment, but not combinants alone, resulted tumor-free long-term survival 40% mice without significant toxicity 83% survivors had immune memory specific cells. Treatment also decreased suppression induced tumor. Full response treatment required functional CD8+ T cells, whereas depletion natural killer cells caused only reduction rate. A serum “biomarker” profile that correlated with, seemed predictive of, identified nuclear magnetic resonance–based metabonomic analysis. The nontoxic potential be able predict which individual is responding are characteristics make chemoimmunotherapy attractive clinical testing. (Cancer Res 2006; 66(10): 5419-26)